Diagnosis of Idiopathic Environmental Intolerance
Customize your policy alerts
Sign up for medical mutual - ohio Policy AHS - G2056 alerts
Get alerted when Policy AHS - G2056 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage stance for tests and evaluations used to diagnose idiopathic environmental intolerance (IEI, formerly multiple chemical sensitivity) and related proprietary laboratory panels; applies to Medical Mutual - Ohio members and providers seeking coverage determinations.
CC7 edited for clarity and consistency with enforcement, as breath hydrogen/methane testing is allowed under certain circumstances.
CC2 and CC3 replaced 'In all circumstances' with 'For asymptomatic individuals and/or during general encounters without abnormal findings,' for clarity of enforcement.
Former Section IV. Reimbursement Policy was removed.
Revised code description for CPT code 83015, 83018 (effective date 1/1/2026).
Coverage Criteria
Not Medically Necessary for Diagnosis of IEI
Tests and panels intended to confirm IEI are not covered.
Primary exclusion
- Examples: profiling for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (DDE/DDT), metals testing in blood/urine/cerebrospinal fluid/fingernails/hair, micronutrient and intracellular nutrient panels, oxidative stress/detoxification/methylation testing, lipoic acid/CoQ10 panels, organic acid panels, food sensitivity panels when used to diagnose IEI, and proprietary multi-analyte panels (e.g., Genova Organix, NutrEval, SpectraCell Micronutrient, Vibrant Wellness, Metabolomix+)
Document lists numerous specific specimen types and proprietary panels as not meeting coverage criteria
Guideline-based testing recommendations
Guideline recommendations relevant to testing for SIBO and carbohydrate maldigestion
Recommendations are guideline suggestions, not explicit payer coverage rules.
Guidance emphasizes conditional recommendations.
Covered diagnostic testing (excerpt)
Coverage includes targeted diagnostic testing when criteria are met; breath hydrogen/methane testing is covered for suspected bacterial overgrowth.
Aligns with North American Consensus and referenced guideline literature for breath testing.
The policy explicitly states that laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance (IEI) do not meet coverage criteria. This includes testing of blood, saliva, serum, plasma, urine, stool, hair, fingernails, and cerebrospinal fluid when performed specifically to diagnose IEI, and profiling for volatile solvents, organic acids, organophosphates, phthalates, parabens, and chlorinated pesticides (e.g., DDE/DDT) in asymptomatic individuals or during general encounters without abnormal findings. These specimen types and analyte profiles are considered not medically necessary for diagnosis of IEI and are subject to denial when billed for that purpose.
Several prominent professional societies have expressed skepticism about IEI/MCS and have discouraged nonvalidated testing approaches. The American Medical Association (AMA) stated that multiple chemical sensitivity should not be recognized as a syndrome until reproducible, well-controlled studies are available. The American Academy of Allergy, Asthma and Immunology (AAAAI) has advised that many nonvalidated immune-based tests used to suggest an immunologic basis for IEI are expensive and not useful, and should be discouraged. The American College of Occupational and Environmental Medicine (ACOEM) likewise found no consistent physical findings or laboratory abnormalities to support routine testing for IEI, and the French ANSES appraisal did not recommend specific testing methods for electromagnetic hypersensitivity, suggesting psychological assessment when indicated.
The policy revision history notes that the previous Section IV. Reimbursement Policy was removed. The removal was made because that section relied on industry-standard unit restrictions rather than science-driven limits and was creating confusion; enforcement will instead rely on the coverage criteria described elsewhere in this policy.
The policy enumerates numerous proprietary multi-analyte panels and broad analyte testing that have been marketed for IEI evaluation but lack evidence to support their use for diagnosis. Examples include Genova Diagnostics panels (Organix Comprehensive Profile, NutrEval, GI Effects Profile, SIBO Profile), SpectraCell Micronutrient and antioxidant/function panels, Metabolomix+, Life Extension nutrient panels, and Vibrant Wellness intracellular/extracellular nutrient testing. The document indicates these types of proprietary panels and large-scale analyte profiles are not appropriate to confirm IEI.
Professional statements cited in the policy discourage the use of many nonvalidated tests proposed for IEI/MCS. The AAAAI position specifically characterizes many such immune-based tests as expensive and not useful; ACOEM and the AMA have raised similar concerns about lack of consistent laboratory abnormalities to support routine diagnostic testing. ANSES likewise found no conclusive evidence to support specific testing for electromagnetic hypersensitivity, recommending psychological evaluation where appropriate. Collectively these statements caution providers against ordering tests that lack established clinical validity and utility for IEI.
The policy cites consensus documents and systematic reviews that do not support indiscriminate testing for IEI. References include the 1999 international consensus on multiple chemical sensitivity and recent reviews of SIBO and breath testing literature. The revision history reiterates that literature review did not necessitate changes to coverage criteria and supports selective, guideline-aligned use of testing (for example, breath hydrogen/methane testing for suspected bacterial overgrowth) rather than broad, non–evidence-based panels for IEI.
Coding
| No codes listed |
| 82108 | Aluminum. |
| 82127 | Amino acids; single, qualitative, each specimen. |
| 82136 | Amino acids, 2 to 5 amino acids, quantitative, each specimen. |
| 82139 | Amino acids, 6 or more amino acids, quantitative, each specimen. |
| 82300 | Cadmium. |
| 82379 | Carnitine (total and free), quantitative, each specimen. |
| 82380 | Carotene. |
| 82441 | Chlorinated hydrocarbons, screen. |
| 82495 | Chromium. |
| 82507 | Citrate. |
| 83655 | Lead |
| 83735 | Magnesium |
| 83785 | Manganese |
| 83885 | Nickel |
| 83918 | Organic acids; total, quantitative, each specimen |
| 83919 | Organic acids; qualitative, each specimen |
| 83921 | Organic acid, single, quantitative |
| 84134 | Prealbumin |
| 84255 | Selenium |
| 84446 | Tocopherol alpha (Vitamin E) |
Provider Actions and Documentation
Pre-authorize IEI-directed panels when payer requires
Prior authorization is required where the plan's coverage rules prohibit testing for IEI; laboratory panels and proprietary multi‑analyte tests used to support an IEI diagnosis do not meet coverage criteria and should be pre-authorized when the payer requires it.
- Applies to proprietary panels and broad analyte profiling intended to confirm IEI.
- Obtain PA consistent with member benefits if the plan restricts IEI-directed testing.
Verify PA for listed CPT/HCPCS codes before ordering
Verify payer-specific prior authorization requirements when ordering any of the CPT/HCPCS procedure codes listed in the policy; these codes are associated with tests discussed in this document and may be subject to PA.
Follow payer PA rules for breath hydrogen/methane testing (CPT 91065)
The document does not specify a separate prior authorization process for breath hydrogen/methane testing; when a payer requires PA, support requests for tests such as CPT 91065 with documentation of suspected bacterial overgrowth/SIBO and clinically compatible symptoms.
- If PA is required by the member's benefits, include clinical indication for suspected SIBO and prior evaluation findings.
Use initial noninvasive breath testing and correlate with clinical findings
For breath testing related to suspected SIBO, consider initial noninvasive breath testing (lactulose or glucose) and interpret results together with the patient's clinical presentation before advancing to further invasive testing or specific therapy.
- Use test results in conjunction with compatible symptoms and absence of another explanatory diagnosis.
- Select substrate (lactulose or glucose) appropriate to the clinical question.
Follow guideline-based indications and methods for breath testing
Use breath hydrogen and/or methane testing selectively per guideline suggestions: test for suspected SIBO, carbohydrate maldigestion, and evaluate methane when constipation is prominent; perform fructose and lactose breath tests for at least 3 hours when indicated.
- North American Consensus and ACG recommend breath testing for SIBO and carbohydrate maldigestion in symptomatic patients.
- Evaluate methane excretion when associated with constipation; perform fructose/lactose breath testing for ≥3 hours as recommended.
Provider action — local implementation / author note
Placeholder — see policy sections on proprietary testing, breath testing, and applicable codes; author should confirm any additional payer-specific procedural requirements or local implementation notes here.
Complete clinical evaluation (history, exam, baseline labs, exposure and symptom screening)
Perform a focused clinical evaluation prior to ordering diagnostic testing: obtain history and physical exam, basic laboratory studies (CBC, serum electrolytes, glucose, urinalysis), occupational/environmental exposure history, and consider standardized screening questionnaires (EESI, PHQ‑9) to document symptoms and comorbidity.
- Document symptom pattern, exposures, and psychiatric screening where appropriate.
- Use occupational/environmental history and symptom questionnaires to support clinical indication.
Ensure LDT validation and CLIA compliance when ordering IEI tests
Laboratory‑developed tests (LDTs) referenced for IEI are developed and run in‑house and are regulated by CMS under CLIA as high‑complexity tests; providers ordering or using LDTs should ensure appropriate laboratory CLIA compliance and validation.
- LDTs are not FDA‑cleared; validation and CLIA high‑complexity oversight are required.
Document clinical indication and suspected SIBO when ordering breath testing
Document the clinical indication supporting any test ordered under this policy (refer to the CPT/HCPCS list) and, for breath hydrogen/methane testing, specifically document suspected bacterial overgrowth (including SIBO) and compatible symptoms to meet coverage criteria.
- Include symptom description, prior evaluations, and rationale linking testing to the clinical concern (e.g., suspected SIBO).
- Attach relevant questionnaire results or exposure history when available.
Claims for IEI-confirmatory tests will be denied
Claims for laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance will be denied because such tests do not meet coverage criteria; avoid ordering tests intended solely to 'confirm' IEI for coverage purposes.
- This includes proprietary multi‑analyte panels and broad analyte profiling when used to diagnose IEI.
- Order only tests with a documented clinical indication consistent with policy criteria.
Claims may be denied due to LCD/NCD precedence — verify government policies
Claims may be denied or determined by applicable government policy (LCD/NCD) when those federal or state rules take precedence over this policy; verify Medicare/Medicaid coverage and LCD/NCD guidance for the member.
- If a conflict exists between this policy and an applicable government policy, the government policy governs the determination.
Claims not meeting explicit coverage criteria are denial triggers
Claims for tests or procedures that do not meet the explicit coverage criteria in this policy may be denied; removal of the prior reimbursement section means enforcement relies on coverage criteria rather than unit‑based restrictions.
- Ensure ordered tests clearly meet the coverage language (e.g., breath hydrogen/methane testing for suspected bacterial overgrowth).
Background
Idiopathic environmental intolerance (IEI) is described as a subjective syndrome of recurrent, nonspecific symptoms that patients attribute to low-level environmental exposures. The condition lacks consistent objective diagnostic findings, overlaps with common conditions such as anxiety, irritable bowel syndrome, and fibromyalgia, and frequently coexists with psychiatric comorbidity. Because symptoms and triggers are variable and subjective, standard evaluation emphasizes a careful history, physical exam, basic laboratory testing, occupational/environmental exposure history, and targeted testing only when clinically indicated rather than broad screening for IEI.
Definitions
References and Revision History
The policy includes an extensive reference list supporting its positions and guidance. Citations include professional society position statements, consensus documents, guideline reviews of breath testing and SIBO, and recent clinical reviews and primary studies; the reference section lists over 30 evidence sources used to inform the coverage stance and clinical recommendations.
Policy effective date updated to 2026-06-01.
Reviewed and updated background, guidelines/recommendations, and evidence-based references; clarified wording in coverage criteria including allowing breath hydrogen/methane testing for bacterial overgrowth (including SIBO); removed former reimbursement policy section; revised code descriptions for CPT 83015 and 83018 effective 2026-01-01.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.